clinical trial Jan 17, 2023 Yantai LNC Biotechnology to Use Sofie Biosciences Imaging Agent to ID Patients for Theranostic Trial Jan 17, 2023 Lantern Pharma Preparing IND for Synthetic Lethality Program With FDA Feedback Jan 11, 2023 Bio4t2 Begins Dosing Solid Tumor Patients in First-In-Human CAR T-Cell Therapy Trial Jan 10, 2023 Immunocore Unveils New T-Cell Receptor Therapy Candidates, Estimates $140M in 2022 Kimmtrak Sales Jan 9, 2023 Ideaya to Launch PARG Inhibitor Trial in Homologous Recombination Repair-Deficient Cancers Jan 6, 2023 BioNTech, UK Government to Expand Access to Personalized mRNA Cancer Vaccines in England Jan 5, 2023 Theseus Reveals Development Milestones for its Precision Oncology Programs in 2023 Jan 4, 2023 Orano Med Commences Phase I Trial of Lead Radiopharmaceutical in GRPR-Expressing Solid Tumors Jan 3, 2023 Evaxion Cleared by FDA to Begin Phase IIb Trial of Cancer Vaccine, Keytruda in Melanoma Dec 22, 2022 FDA Clears Iaso Biotherapeutics for US Trials of BCMA-Targeted CAR-T Therapy in Multiple Myeloma Dec 22, 2022 Gilead Sciences, Arcus Biosciences Tout Domvanalimab NSCLC Data as Good News for Anti-TIGIT Approach Premium Dec 22, 2022 OneChain Immunotherapeutics to Launch CD1a-Targeting CAR T-Cell Therapy Trial in T-Cell Leukemia Dec 21, 2022 Jazz Takes Up Option on Zymeworks' HER2-Targeted Bispecific Antibody Dec 20, 2022 Invectys, CTMC Begin First-in-Human Trial of HLA-G-Targeting CAR T-Cell Therapy in Solid Tumors Dec 20, 2022 Moderna's Oncology Aspirations Grow With mRNA Vaccine Success in Melanoma Premium Dec 19, 2022 AstraZeneca's Imfinzi Fails to Meet Primary Endpoint in PD-L1-high NSCLC Dec 19, 2022 Carrick Therapeutics, Menarini Group Studying Samuraciclib With Elacestrant Dec 15, 2022 AnHeart Therapeutics Gets FDA Clearance to Study Safusidenib in IDH1-Mutant Glioma Patients Dec 14, 2022 Ellipses Begins Phase I/II Trial of EP0031 in RET-Altered Tumors Dec 13, 2022 Gilead's Yescarta Safe and Effective for CNS Lymphoma Patients, Pilot Study Shows Premium Load More Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer